Cervical Cancer
Chicago, IL—The addition of the PD-1 inhibitor pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in a substantial and clinically meaningful improvement in overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer, according to the final OS analysis of the phase 3 KEYNOTE-826 trial.
Health insurance coverage mediated racial and ethnic inequities among patients with advanced-stage cervical cancer, according to findings from a recent retrospective, cross-sectional, population-based study.
Vaccination against human papillomavirus can prevent several types of cancer, including cervical, oral/oropharyngeal, penile, and anal cancers.
By William King
The addition of pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in significantly and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) in women with cervical cancer.